Shop Now Contact

iF647 Anti-human CD269 (BCMA) Antibody

Cat # Size Price Quantity
11400125 tests$150

  Bulk/Custom

Product Details

CloneBelantamab
ApplicationFlow Cytometry
ReactivityHuman
FormatiF647
Target NameBCMA, BCM, TNFRSF17, CD269
IsotypeHuman IgG1
Antibody TypeMonoclonal
Regulatory StatusRUO
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
Protein ConcentrationSupplied at a lot-specific concentration.
Storage&HandlingThe antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Recommended UsageFor flow cytometric staining, it is recommended to use 5 uL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application.
Excitation LaserRed Laser (633 nm)
Research AreasPlasma cells, Cancer Marker, Autoimmunity
See All FormatsClone Belantamab

Background Information

Human :contentReference[oaicite:0]{index=0} (B cell maturation antigen, also known as TNFRSF17) is a member of the tumor necrosis factor receptor superfamily primarily expressed on plasma cells and a subset of mature B cells. BCMA plays a key role in regulating B cell survival, differentiation, and antibody production, making it essential for humoral immunity.

Structurally, BCMA is a type III transmembrane protein with a short extracellular domain, a single transmembrane region, and an intracellular tail that mediates downstream signaling. Its principal ligands are :contentReference[oaicite:1]{index=1} and :contentReference[oaicite:2]{index=2}, which bind BCMA to activate signaling pathways such as NF-κB, promoting plasma cell survival and longevity.

In disease, BCMA is highly expressed in multiple myeloma and other plasma cell malignancies, where it supports tumor cell survival and resistance to apoptosis. Elevated soluble BCMA levels in serum are also used as a biomarker for disease burden and progression.

Therapeutically, BCMA is a major target in cancer immunotherapy. Approaches include monoclonal antibodies, antibody-drug conjugates, bispecific T cell engagers, and CAR-T cell therapies designed to selectively eliminate BCMA-expressing malignant plasma cells. These strategies have shown significant clinical efficacy, positioning BCMA as one of the most important targets in multiple myeloma treatment.

Isotype Control

iF647 Human IgG1 Isotype Control Antibody

Data Sheets

iF647 Anti-human CD269 (BCMA) Antibody TDS

Related Protocols

Flow Cytometry Protocol

Frequently Asked Questions

How do I determine the optimal antibody concentration/titer for my experiment?
We recommend titrating each new antibody lot on your own cell type and instrument, since optimal concentration depends on cell density, target expression level, and cytometer sensitivity. Suggested starting dilutions or test sizes (e.g., µg or µl per 10^6 cells) are provided on the product page as a starting reference point, not a fixed requirement.
Can these antibodies be used for intracellular or intranuclear staining, or only surface staining?
Intended use (surface, intracellular, or both) is specified per product, indicated under Application. The appropriate Related Protocol is linked for each product. If you need to detect both surface and intracellular markers in the same panel, confirm each antibody's compatibility with your fixation/permeabilization protocol before combining them.
What controls should I use alongside these antibodies?
Matched isotype controls (same host species, isotype, and conjugate) are available for most clones to help distinguish specific binding from background/non-specific staining and are linked on each product page. Unstained, single-color compensation, and fluorescence-minus-one (FMO) controls are also recommended, especially for multicolor panel design.
Can I combine InnoCyto Flow Cytometry antibodies into a multicolor panel?
Yes — antibodies across our catalog are designed to be panel-compatible, and conjugate options are offered specifically to support multiplexing. When building a panel, pair bright fluorophores with low-expression targets, avoid excessive spectral overlap, and confirm compensation is set up correctly for your specific fluorochrome combination. Use our Panel Builder to simplify the process.

Have a product or application question? Consult our FAQs or contact us.